Menu
Not yet recruiting NCT07653139

Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany

Observational Haemophilia A

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: No treatment given.
Who it may be relevant to
Registry conditions: Haemophilia A. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.

Interventions

  • Other No treatment given
    Web-based survey

Primary outcome measures

  • Choice of treatment alternative in discrete choice tasks [Time frame: Day 1]

Eligibility criteria

Inclusion criteria

  • Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  • Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey.
  • Age above or equal to 18 years at the time of signing informed consent.
  • Validated diagnose with haemophilia A, with and without inhibitors.
  • Resident in Germany.

Exclusion criteria

  • No provision of informed consent in this study.
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • Age below 18 years at the time of signing informed consent.
  • Absence of a diagnosis of haemophilia A.
  • No residence in Germany.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Germany · 1 center
  • Novo Nordisk Investigational Site — Mainz

Identifiers

NCT: NCT07653139 · DAS-8858 · U1111-1336-6966

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗